Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients
Open Access
- 1 July 2007
- journal article
- clinical trial
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (7) , 2487-2495
- https://doi.org/10.1210/jc.2006-0723
Abstract
Background: Serum thyroglobulin (Tg) is the marker of differentiated thyroid cancer after initial treatment and TSH stimulation increases its sensitivity for the diagnosis of recurrent disease. Aim: The goal of the study is to compare the diagnostic values of seven methods for serum Tg measurement for detecting recurrent disease both during L-T4 treatment and after TSH stimulation. Methods: Thyroid cancer patients who had no evidence of persistent disease after initial treatment (total thyroidectomy and radioiodine ablation) were studied at 3 months on L-T4 treatment (Tg1) and then at 9–12 months after withdrawal or recombinant human TSH stimulation (Tg2). Sera with anti-Tg antibodies or with an abnormal recovery test result were excluded from Tg analysis with the corresponding assay. The results of serum Tg determination were compared to the clinical status of the patient at the end of follow-up. Results: Thirty recurrences were detected among 944 patients. A control 131I total body scan had a low sensitivity, a low specificity, and a low clinical impact. Assuming a common cutoff for all Tg assays at 0.9 ng/ml, sensitivity ranged from 19–40% and 68–76% and specificity ranged from 92–97% and 81–91% for Tg 1 and Tg2, respectively. Using assays with a functional sensitivity at 0.2–0.3 ng/ml, sensitivity was 54–63% and specificity was 89% for Tg1. Using the two methods with a lowest functional sensitivity at 0.02 and 0.11 ng/ml resulted in a higher sensitivity for Tg1 (81% and 78%), but at the expense of a loss of specificity (42% and 63%); finally, for these two methods, using an optimized functional sensitivity according to receiver operating characteristic curves at 0.22 and 0.27 ng/ml resulted in a sensitivity at 65% and specificity at 85–87% for Tg1. Conclusion: Using an assay with a lower functional sensitivity may give an earlier indication of the presence of Tg in the serum on L-T4 treatment and may be used to study the trend in serum Tg without performing any TSH stimulation. Serum Tg determination obtained after TSH stimulation still permits a more reliable assessment of cure and patient’s reassurance.Keywords
This publication has 23 references indexed in Scilit:
- Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine TherapyJournal of Clinical Endocrinology & Metabolism, 2006
- Follow-Up of Low Risk Patients with Papillary Thyroid Cancer: Role of Neck Ultrasonography in Detecting Lymph Node MetastasesJournal of Clinical Endocrinology & Metabolism, 2004
- Diagnostic value of serum thyroglobulin measurements in the follow‐up of differentiated thyroid carcinoma, a structured meta‐analysisClinical Endocrinology, 2004
- Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2003
- Diagnosis of neck recurrences in patients with differentiated thyroid carcinomaCancer, 2002
- Relationship Between Tumor Burden and Serum Thyroglobulin Level in Patients with Papillary and Follicular Thyroid CarcinomaThyroid®, 2002
- Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial TreatmentJournal of Clinical Endocrinology & Metabolism, 2002
- Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer?Journal of Clinical Endocrinology & Metabolism, 2000
- Combination of Radioiodine (131I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 1998
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998